Chlorproguanil/dapsone/artesunate: Difference between revisions
Content deleted Content added
mNo edit summary |
Cholerashot (talk | contribs) m Only one of those four tags makes any sense for this version of the article |
||
| Line 1: | Line 1: | ||
{{technical}} |
{{technical}} |
||
{{importance}} |
|||
{{tense}} |
|||
{{globalize}} |
|||
'''Chlorproguanil-dapsone-artesunate''' (abbreviated '''CDA''') is a new antimalarial treatment that entered Phase III clinical trials in 2006. It is being compared against artemether-lumefantrine ([[Coartem]]®) and against chlorproguanil-dapsone [[Lapdap]]™. This drug is being developed in collaboration between [[GlaxoSmithKline]], [[UNICEF]], the [[World Bank Group|World Bank]], [[Medicines for Malaria Venture]] and the [[World Health Organisation|WHO]] [[Special Programme for Research and Training in Tropical Diseases]] (WHO/TDR), the [[Liverpool School of Tropical Medicine]], and the [[London School of Hygiene and Tropical Medicine]].<ref>{{cite journal | journal=Lancet Infect Dis | year=2006 | volume=6 | issue=9 | pages=551 | author=Das P | title=Promising anti-malarial enters phase II studies. }}</ref> |
'''Chlorproguanil-dapsone-artesunate''' (abbreviated '''CDA''') is a new antimalarial treatment that entered Phase III clinical trials in 2006. It is being compared against artemether-lumefantrine ([[Coartem]]®) and against chlorproguanil-dapsone [[Lapdap]]™. This drug is being developed in collaboration between [[GlaxoSmithKline]], [[UNICEF]], the [[World Bank Group|World Bank]], [[Medicines for Malaria Venture]] and the [[World Health Organisation|WHO]] [[Special Programme for Research and Training in Tropical Diseases]] (WHO/TDR), the [[Liverpool School of Tropical Medicine]], and the [[London School of Hygiene and Tropical Medicine]].<ref>{{cite journal | journal=Lancet Infect Dis | year=2006 | volume=6 | issue=9 | pages=551 | author=Das P | title=Promising anti-malarial enters phase II studies. }}</ref> |
||
Revision as of 20:03, 12 April 2008
 | This article may be too technical for most readers to understand. |
Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006. It is being compared against artemether-lumefantrine (Coartem®) and against chlorproguanil-dapsone Lapdap™. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.[1]
References
- ^ Das P (2006). "Promising anti-malarial enters phase II studies". Lancet Infect Dis. 6 (9): 551.
External links
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |